New Investigation Exposes Dangerous Abortion Pill Practices
A troubling investigation reveals how chemical abortion continues to put women at serious risk.
Live Action’s undercover investigation found that Planned Parenthood facilities fail to implement basic safety protocols when distributing mifepristone and misoprostol — the two drugs that make up the RU-486 abortion regimen.
Women receive these dangerous drugs without ultrasounds, medical screenings, or proper follow-up appointments.
The investigation shows abortionists are operating more like drug dispensaries than medical facilities.
This is deeply troubling, given that research shows nearly 11% of women experience serious health complications from abortion pills. A recent study by the experts at the Ethics and Public Policy Center found the abortion drugs mifepristone and misoprostol are at least 22 times more dangerous than the U.S. Food and Drug Administration labeling indicates. Complications from these abortion drugs include sepsis, infection, and life-threatening hemorrhage.
Making matters worse, instead of cracking down on abortion drugs, the FDA approved a generic version of mifepristone in September, and lawmakers in some states have enacted “shield laws” to protect abortionists who ship abortion drugs across the country. If an abortionist in one of these states mails abortion drugs to Arkansas, the state’s “shield law” prevents the abortionist from being prosecuted.
Groups like Planned Parenthood have also opened abortion facilities within driving distance of pro-life states, and abortionists are spending millions of dollars to promote abortion to women in Arkansas and elsewhere. Those are all serious problems.
There is nothing “safe” about abortion drugs. Abortion drugs kill unborn children and they hurt women. They simply should not be for sale in America.
For more information on this investigation, visit LifeNews.com and Live Action’s report.
Articles appearing on this website are written with the aid of Family Council’s researchers and writers.





